Exelixis, Inc. (EXEL) announced that the FDA has notified it about an update to its supplemental new drug application (sNDA) for cabozantinib.The sNDA is seeking approval for cabozantinib for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET).In November 2024, the FDA notified the company that the sNDA for cabozantinib for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and ad ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Shares of Exelixis, Inc. (EXEL) have surged 50% in a year against the industry’s decline of 16.1%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The company's stellar performance can be attributed to the strong growth of its lead drug, Cabometyx, raised guidance and encouraging pipeline progress.EXEL Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchCabometyx Boosts EXELCabometyx maintained its status as the leading tyrosine kinase inhibitor (T ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Incyte (INCY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while o ...

ROTTERDAM, The Netherlands, Dec. 17, 2024 /PRNewswire/ -- Sairopa B.V., today announced it has achieved a milestone event in its exclusive clinical development and option agreement with Exelixis, Inc. (Nasdaq: EXEL) involving ADU-1805, an innovative anti-SIRPα antibody with the potential to enhance the immune system's ability to combat cancer. Under the terms of the agreement, Exelixis has an exclusive option to license worldwide development and commercialization rights for ADU-1805 and other anti-SIRPα ant ...

A month has gone by since the last earnings report for Exelixis (EXEL) . Shares have added about 10.8% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Exelixis due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Exelixis Beats on Q3 Earnings and Sales, Raises Annual O ...

Exelixis, Inc. (EXEL) announced that its supplemental new drug application (sNDA) for cabozantinib will be discussed at an Oncologic Drugs Advisory Committee (“ODAC”) meeting in March 2025.The sNDA is seeking approval for the drug to treat adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET).Exelixis’ shares have surged 48.9% year to date against the industry’s decline of 7.8%.Image Source: Zacks Investment ResearchDetails of EXEL’s sNDA f ...

Shares of Exelixis, Inc. (EXEL) have surged 25% in a month against the industry’s decline of 4.9%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The outperformance can be attributed to better-than-expected third-quarter results. The company also raised its annual guidance.Exelixis has been a consistent outperformer of late on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress.EXEL Outperforms Industry, Sector & S&P 500Image So ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Z ...